PER 1.41% 7.0¢ percheron therapeutics limited

FDA approves Sareptas Srp901 for the whole population

  1. 13,147 Posts.
    lightbulb Created with Sketch. 1380
    Wow!
    It matters not to PER
    Why?

    1) Boys that can access the gene therapy drug will get it
    others will use other therapies..
    2)The cost $3.2 million will be a stumbling block
    3) US clinicians are skeptical re efficacy
    4)Sarepta is yet to make a profit from the other exon skipping drug
    5)Gene therapy has still got a long way to go before it’s widely accepted
    6) All in all PER will continue with its path forward
    Other exon skipping drugs will use combination therapies.. eg Atl1102

    .
    https://finance.yahoo.com/news/sarepta-therapeutics-announces-expanded-us-210200030.html
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.